Merck will be giving with one hand and taking away with the other as it confirms cuts across its discovery and early-stage R&D businesses, but said it will…

Motif Bio is forging ahead with plans to list its stock on Nasdaq to raise the cash it needs to wrap up a Phase III trial of its antibiotic, iclaprim.

Novartis-backed gene therapy player GenSight is looking to bounce back from its failure to list on Nasdaq by pulling off a €40 million IPO in Paris.

He’s only been Arena’s president and CEO for two months, but biotech vet Amit Munshi is wasting no time getting to know his new staff as the company announces…

Syros Pharmaceuticals aims to use small molecules to control the activation and repression of genes. Now, it has raised $50 million in an IPO to get proof-of-…

It was a shock result for the U.K. this morning as the public decided by a narrow margin of 52-48 to leave the European Union, in what will have a profound…

Eleven Biotherapeutics, which has valiantly (or stubbornly) carried on over the past 12 months despite a slew of major trial failures, is now, finally, nearing…

On June 17, Neil Woodford upped his stake in Circassia. The next business day, Circassia posted Phase III trial data that caused its stock price to crash.